Core Viewpoint - Hercules Capital, Inc. is facing a class action lawsuit for securities fraud, with allegations of misleading investors regarding its loan origination process and portfolio valuation [4]. Group 1: Lawsuit Details - The Schall Law Firm is leading a class action lawsuit against Hercules Capital, Inc. for violations of the Securities Exchange Act of 1934 [1]. - Investors who purchased Hercules securities between May 1, 2025, and February 27, 2026, are encouraged to participate in the lawsuit [2]. - The lawsuit claims that Hercules made false and misleading statements about its due diligence and portfolio investments, leading to investor losses when the truth was revealed [4]. Group 2: Investor Participation - Investors are urged to contact the Schall Law Firm to discuss their rights and potential participation in the lawsuit [3]. - The class for the lawsuit has not yet been certified, meaning that investors are not currently represented by an attorney unless they take action [3]. Group 3: Legal Representation - The Schall Law Firm specializes in securities class action lawsuits and represents investors globally [5].

Core Viewpoint - A class action lawsuit has been filed against Paysafe Limited (NYSE: PSFE) for allegedly misleading investors about its business prospects during the period from March 4, 2025, to November 12, 2025 [2][4]. Group 1: Allegations and Issues - The lawsuit claims that Paysafe failed to disclose significant risks, including heavy reliance on a single high-risk client, which led to understated credit loss reserves and write-offs [2]. - It is alleged that Paysafe had undisclosed issues with higher risk Merchant Category Codes, complicating its banking relationships [2]. - These undisclosed issues are believed to have negatively impacted the company's revenue growth and overall revenue mix, making it unlikely for Paysafe to meet its financial guidance for fiscal year 2025 [2]. Group 2: Stock Price Impact - Following the revelation of these issues, Paysafe's stock price dropped by $2.80, or 27.6%, closing at $7.36 per share on November 13, 2025 [3]. Group 3: Shareholder Actions - Shareholders who wish to participate in the class action must submit their papers to the court by April 7, 2026, to serve as lead plaintiff [4]. - Shareholders are not required to participate in the case to be eligible for recovery and can remain absent class members if they choose [4].

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Picard Medical, Inc. (NYSE: PMI) securities between September 2, 2025, and October 31, 2025, due to allegations of a fraudulent stock promotion scheme [1][2]. Group 1: Allegations and Company Background - Picard Medical, Inc. is involved in the design, manufacturing, production, supply, marketing, and sale of medical device products [1]. - The allegations against Picard Medical include failure to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [2]. - Insiders and/or affiliates allegedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign, with public statements omitting mention of false rumors and artificial trading activity [2]. Group 2: Stock Performance and Impact - On October 24, 2025, Picard's stock price experienced a significant crash, dropping 70% to $3.99 per share, and has since continued to decline to approximately $2.00 per share [3]. Group 3: Legal Proceedings and Shareholder Actions - Shareholders may be eligible to participate in the class action against Picard Medical, with a deadline for filing as lead plaintiff set for April 3, 2026 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].

Group 1 - Ademi LLP is investigating possible securities fraud claims against ADMA Biologics, Inc. due to potentially inaccurate statements regarding its financial statements, business operations, and prospects [1] - The investigation specifically focuses on the accuracy of ADMA's statements related to accounting for revenue [2]

Core Viewpoint - A securities fraud class action has been filed against monday.com Ltd. for allegedly making materially false statements and failing to disclose adverse facts during the class period from September 17, 2025, to February 6, 2026 [2][6]. Group 1: Lawsuit Details - The lawsuit claims that during the class period, monday.com made misleading statements regarding its financial performance and growth expectations [6]. - On November 10, 2025, monday.com reported third quarter 2025 revenue of $316.9 million but indicated only a modest revenue increase for the fourth quarter, leading to a stock price drop of $23.38, or 12.3%, to close at $166.21 [6][7]. - On February 9, 2026, the company rescinded its $1.8 billion revenue target for 2027 and projected a significant deceleration in growth for 2026, causing the stock price to fall by $20.37, or 20.8%, to close at $77.63 [7]. Group 2: Legal Representation - Glancy Prongay Wolke & Rotter LLP is a law firm specializing in securities litigation, encouraging affected investors to contact them for potential claims [3][8]. - The firm has a strong track record in representing investors and has been recognized for its successes in securities class action cases [8].

RR Investor Alert: Richtech Robotics Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit Mar 25, 2026 2:15 PM Eastern Daylight Time RR Investor Alert: Richtech Robotics Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit Share SAN DIEGO--(BUSINESS WIRE)-- Robbins LLPreminds stockholders that a class action was filed on behalf of all investors who purchased or ...

Core Viewpoint - Trip.com Group Limited is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims of misleading statements and failure to disclose regulatory risks associated with its monopolistic practices [4][5]. Company Overview - Trip.com operates as a travel service provider, offering services such as accommodation reservations, transportation ticketing, packaged tours, in-destination services, and corporate travel management [3]. Allegations - The lawsuit alleges that during the class period from April 30, 2024, to January 13, 2026, Trip.com and its executives made false statements and failed to disclose significant regulatory risks, particularly related to antitrust issues [4]. - A Bloomberg article published on January 14, 2026, reported that China is investigating Trip.com for alleged antitrust conduct, which led to a 19% drop in the price of Trip.com American Depositary Shares over two trading sessions [5]. Legal Process - Investors who purchased Trip.com securities during the class period can seek appointment as lead plaintiff in the class action lawsuit, which allows them to represent the interests of all class members [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [7].

Core Viewpoint - A class action lawsuit has been filed against Concorde International Group, Ltd. for failing to disclose involvement in a fraudulent stock promotion scheme, leading to significant investor losses during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague on behalf of investors who acquired Concorde shares from April 21, 2025, to July 14, 2025 [1][2]. - Investors have until May 18, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations and Impact - The complaint alleges that Concorde was subject to a fraudulent scheme involving impersonators who spread false information through social media [3]. - On July 10, 2025, Concorde's share price plummeted approximately 80%, dropping to $5.66 per share, following the artificial inflation of its stock price [4].

Core Viewpoint - A securities fraud class action lawsuit has been filed against uniQure N.V. for misleading investors regarding its gene therapy drug AMT-130 during the specified Class Period [2][4][5]. Group 1: Lawsuit Details - The lawsuit was filed by Kessler Topaz Meltzer & Check, LLP on behalf of investors who purchased uniQure ordinary shares between September 24, 2025, and October 31, 2025 [2][7]. - The case is titled Scocco v. uniQure N.V., et al., and was filed in the United States District Court for the Southern District of New York [2]. - Investors have until April 13, 2026, to move the Court to serve as lead plaintiff for the class [3][9]. Group 2: Allegations Against uniQure - The complaint alleges that uniQure made materially false and misleading statements regarding its Phase I/II clinical trials and the timeline for its Biologics License Application (BLA) submission to the FDA [4][5]. - Specific allegations include that the design of the Pivotal Study was not fully approved by the FDA and that uniQure downplayed the likelihood of needing to delay its BLA timeline due to additional studies [5]. - The lawsuit claims that these misrepresentations led to a significant drop in the company's share price when the truth about the BLA submission was revealed [6][8]. Group 3: Impact on Share Price - Following the revelation on November 3, 2025, uniQure's share price fell by $33.40, or over 49%, from $67.69 to $34.29 per share [6][8]. Group 4: Investor Actions - Investors who have lost money on their investment in uniQure are encouraged to contact Kessler Topaz Meltzer & Check, LLP for legal rights and recovery options [3][10]. - The lead plaintiff process allows investors to represent the class in litigation, with no obligation to take action if they choose not to [9].

Core Viewpoint - A class action lawsuit has been filed against Coty Inc. and certain officers for alleged violations of federal securities laws during the specified class period from November 5, 2025, to February 4, 2026 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased Coty securities during the class period [2]. - The complaint alleges that defendants made materially false and misleading statements regarding Coty's growth and profitability prospects for fiscal year 2026 [3]. - Specific allegations include: - Overwhelmingly positive statements about Coty's growth and profitability [3]. - Slowing growth in the beauty market, particularly underperformance in the Consumer Beauty segment [3]. - Pressure on the company's margins due to increased marketing expenditures [3]. - Deceleration in growth within Coty's Prestige fragrance segment [3]. - Overall, defendants' statements about Coty's business and prospects were materially false and misleading [3]. Group 2: Next Steps for Investors - Investors wishing to join the lawsuit can review the complaint on the law firm's website or contact the firm's representatives [4]. - The deadline for investors to request appointment as lead plaintiff is May 22, 2026 [4]. - Participation in any recovery does not require serving as lead plaintiff [4]. Group 3: Legal Representation - Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [5]. - The firm has a strong track record, having recovered hundreds of millions of dollars for investors nationwide [6]. - The firm's focus is on restoring investor capital and ensuring corporate accountability [6].